FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.

"availability of data and materials the datasets used and/or analyzed during the current study are available from the geo ( https://www ncbi nlm nih gov/geo/ ) tcga ( https://cancergenome nih gov/ ) beataml2 ( https://biodev github io/beataml2/ ) and proteomic and phosphoproteomic landscapes of aml ( http://www leylab org/amlproteome )."

"availability of data and materials the datasets used and/or analyzed during the current study are available from the geo ( https://www ncbi nlm nih gov/geo/ ) tcga ( https://cancergenome nih gov/ ) beataml2 ( https://biodev github io/beataml2/ ) and proteomic and phosphoproteomic landscapes of aml ( http://www leylab org/amlproteome )."

"Declarations Ethics approval and consent to participateBMMC of AML patients were kindly provided by the Department of Hematology at Ren-Ji Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all the patients, and all the procedures were approved by the Ethics Committee for Medical Research (IRB) at Shanghai Jiao Tong University School of Medicine. All the animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Shanghai Jiao Tong University School of Medicine. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by National Key R&D Program of China (2020YFA0803403); National Natural Science Foundation (91853206, 82270156) and its innovative group support (No.81721004); CAMS Innovation Fund for Medical Sciences (2019-I2M-5-051); and Shanghai Committee of Science and Technology (20JC1410100). All authors declare no competing interests."